Combination anti-Aß treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice

Journal of Experimental Medicine

Volumn 215, Issue 5, 2018, Pages 1349-1364

  Chiang, Angie C A ^a   Fowler, Stephanie W ^a   Savjani, Ricky R ^b   Hilsenbeck, Susan G ^a   Wallace, Clare E ^c   Cirrito, John R ^c   Das, Pritam ^d   Jankowsky, Joanna L ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; DOXYCYCLINE; MAMMALIAN TARGET OF RAPAMYCIN; SYNAPTOPHYSIN; BIOLOGICAL MARKER; TARGET OF RAPAMYCIN KINASE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSOCIATIVE MEMORY; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FUNCTIONAL STATUS; GENE EXPRESSION; GENE REPRESSION; MALE; MEMORY DISORDER; MOUSE; MTOR SIGNALING; NERVE FIBER DEGENERATION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SPATIAL LEARNING; WORKING MEMORY; AMYLOID PLAQUE; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; AXON; C57BL MOUSE; COMBINATION DRUG THERAPY; LYSOSOME; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; SOLUBILITY; SYNAPSE; TRANSGENE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AXONS; BEHAVIOR, ANIMAL; BIOMARKERS; COGNITION; DRUG THERAPY, COMBINATION; IMMUNIZATION, PASSIVE; LYSOSOMES; MICE, INBRED C57BL; MICE, TRANSGENIC; PLAQUE, AMYLOID; SIGNAL TRANSDUCTION; SOLUBILITY; SYNAPSES; TOR SERINE-THREONINE KINASES; TRANSGENES;

EID: 85046808882     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20171484     Document Type: Article

References (90)

1. Alamed, J., D.M. Wilcock, D.M. Diamond, M.N. Gordon, and D. Morgan. 2006. Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat. Protoc. 1:1671-1679. https:// doi .org/ 10 .1038/ nprot .2006 .275
2. An, W.L., R.F. Cowburn, L. Li, H. Braak, I. Alafuzoff, K. Iqbal, I.G. Iqbal, B. Winblad, and J.J. Pei. 2003. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am. J. Pathol. 163:591-607. https:// doi .org/ 10 .1016/ S0002 -9440(10)63687 -5
3. Bard, F., C. Cannon, R. Barbour, R.L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, et al. 2000. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:916-919. https:// doi .org/ 10 .1038/ 78682
4. Bayat Mokhtari, R., T.S. Homayouni, N. Baluch, E. Morgatskaya, S. Kumar, B. Das, and H. Yeger. 2017. Combination therapy in combating cancer. Oncotarget. 8:38022-38043.
5. Berger, Z., B. Ravikumar, F.M. Menzies, L.G. Oroz, B.R. Underwood, M.N. Pangalos, I. Schmitt, U. Wullner, B.O. Evert, C.J. O'Kane, and D.C. Rubinsztein. 2006. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15:433-442. https:// doi .org/ 10 .1093/ hmg/ ddi458
6. Bockaert, J., and P. Marin. 2015. mTOR in brain physiology and pathologies. Physiol. Rev. 95:1157-1187. https:// doi .org/ 10 .1152/ physrev .00038 .2014
7. Caccamo, A., S. Majumder, A. Richardson, R. Strong, and S. Oddo. 2010. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments. J. Biol. Chem. 285:13107-13120. https:// doi .org/ 10 .1074/ jbc .M110 .100420
8. Caccamo, A., M.A. Maldonado, S. Majumder, D.X. Medina, W. Holbein, A. Magrí, and S. Oddo. 2011. Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J. Biol. Chem. 286:8924-8932. https:// doi .org/ 10 .1074/ jbc .M110 .180638
9. Caccamo, A., A. Magrì, D.X. Medina, E.V. Wisely, M.F. López-Aranda, A.J. Silva, and S. Oddo. 2013. mTOR regulates tau phosphorylation and degradation: Implications for Alzheimer's disease and other tauopathies. Aging Cell. 12:370-380. https:// doi .org/ 10 .1111/ acel .12057
10. Calabrese, B., G.M. Shaked, I.V. Tabarean, J. Braga, E.H. Koo, and S. Halpain. 2007. Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-beta protein. Mol. Cell. Neurosci. 35:183-193. https:// doi .org/ 10 .1016/ j .mcn .2007 .02 .006
11. Chakrabarty, P., A. Li, C. Ceballos-Diaz, J.A. Eddy, C.C. Funk, B. Moore, N. DiNunno, A.M. Rosario, P.E. Cruz, C. Verbeeck, et al. 2015. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron. 85:519-533. https:// doi .org/ 10 .1016/ j .neuron .2014 .11 .020
12. Chiang, A.C.A., S.W. Fowler, R. Reddy, O. Pletnikova, J.C. Troncoso, M.A. Sherman, S.E. Lesne, and J.L. Jankowsky. 2018. Discrete pools of oligomeric amyloid-beta track with spatial learning deficits in a mouse model of Alzheimer amyloidosis. Am. J. Pathol. 188:739-756.
13. Chiang, A.C.A., S.W. Fowler, R. Reddy, O. Pletnikova, J.C. Troncoso, M.A. Sherman, S.E. Lesne, and J.L. Jankowsky. 2018. Discrete pools of oligomeric amyloid-ß track with spatial learning deficits in a mouse model of Alzheimer amyloidosis. Am. J. Pathol. 188:739-756. https:// doi .org/ 10 .1016/ j .ajpath .2017 .11 .011
14. Chow, V.W., A.V. Savonenko, T. Melnikova, H. Kim, D.L. Price, T. Li, and P.C. Wong. 2010. Modeling an anti-amyloid combination therapy for Alzheimer's disease. Sci. Transl. Med. 2:13ra1. https:// doi .org/ 10 .1126/ scitranslmed .3000337
15. Cirrito, J.R., P.C. May, M.A. O'Dell, J.W. Taylor, M. Parsadanian, J.W. Cramer, J.E. Audia, J.S. Nissen, K.R. Bales, S.M. Paul, et al. 2003. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. J. Neurosci. 23:8844-8853.
16. Cleary, J.P., D.M. Walsh, J.J. Hofmeister, G.M. Shankar, M.A. Kuskowski, D.J. Selkoe, and K.H. Ashe. 2005. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci. 8:79-84. https:// doi .org/ 10 .1038/ nn1372
17. Condello, C., A. Schain, and J. Grutzendler. 2011. Multicolor time-stamp reveals the dynamics and toxicity of amyloid deposition. Sci. Rep. 1:19. https:// doi .org/ 10 .1038/ srep00019
18. Condello, C., P. Yuan, A. Schain, and J. Grutzendler. 2015. Microglia constitute a barrier that prevents neurotoxic protofibrillar Aß42 hotspots around plaques. Nat. Commun. 6:6176. https:// doi .org/ 10 .1038/ ncomms7176
19. Costa-Mattioli, M., and L.M. Monteggia. 2013. mTOR complexes in neurodevelopmental and neuropsychiatric disorders. Nat. Neurosci. 16:1537- 1543. https:// doi .org/ 10 .1038/ nn .3546
20. Crews, L., B. Spencer, P. Desplats, C. Patrick, A. Paulino, E. Rockenstein, L. Hansen, A. Adame, D. Galasko, and E. Masliah. 2010. Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One. 5:e9313. https:// doi .org/ 10 .1371/ journal .pone .0009313
21. DeMattos, R.B., K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul, and D.M. Holtzman. 2001. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 98:8850-8855. https:// doi .org/ 10 .1073/ pnas .151261398
22. De Strooper, B., and L. Chávez Gutiérrez. 2015. Learning by failing: Ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. Annu. Rev. Pharmacol. Toxicol. 55:419-437. https:// doi .org/ 10 .1146/ annurev -pharmtox -010814 -124309
23. Devi, L., and M. Ohno. 2015. A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice. Mol. Brain. 8:19. https:// doi .org/ 10 .1186/ s13041 -015 -0110 -5
24. Dickson, D.W., A. Wertkin, L.A. Mattiace, E. Fier, Y. Kress, P. Davies, and S.H. Yen. 1990. Ubiquitin immunoelectron microscopy of dystrophic neurites in cerebellar senile plaques of Alzheimer's disease. Acta Neuropathol. 79:486-493. https:// doi .org/ 10 .1007/ BF00296107
25. Di Domenico, F., A. Tramutola, C. Foppoli, E. Head, M. Perluigi, and D.A. Butterfield. 2018. mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia. Free Radic. Biol. Med. 114:94-101. https:// doi .org/ 10 .1016/ j .freeradbiomed .2017 .08 .009
26. Dodart, J.C., K.R. Bales, K.S. Gannon, S.J. Greene, R.B. DeMattos, C. Mathis, C.A. DeLong, S. Wu, X. Wu, D.M. Holtzman, and S.M. Paul. 2002. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:452-457. https:// doi .org/ 10 .1038/ nn842
27. Dong, H., M.V. Martin, S. Chambers, and J.G. Csernansky. 2007. Spatial relationship between synapse loss and beta-amyloid deposition in Tg2576 mice. J. Comp. Neurol. 500:311-321. https:// doi .org/ 10 .1002/ cne .21176
28. Dorostkar, M.M., S. Burgold, S. Filser, S. Barghorn, B. Schmidt, U.R. Anumala, H. Hillen, C. Klein, and J. Herms. 2014. Immunotherapy alleviates amyloid-associated synaptic pathology in an Alzheimer's disease mouse model. Brain. 137:3319-3326. https:// doi .org/ 10 .1093/ brain/ awu280
29. Dovey, H.F., V. John, J.P. Anderson, L.Z. Chen, P. de Saint Andrieu, L.Y. Fang, S.B. Freedman, B. Folmer, E. Goldbach, E.J. Holsztynska, et al. 2001. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76:173-181. https:// doi .org/ 10 .1046/ j .1471 -4159 .2001 .00012 .x
30. Ehninger, D., S. Han, C. Shilyansky, Y. Zhou, W. Li, D.J. Kwiatkowski, V. Ramesh, and A.J. Silva. 2008. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat. Med. 14:843-848. https:// doi .org/ 10 .1038/ nm1788
31. Fisher, J.R., C.E. Wallace, D.L. Tripoli, Y.I. Sheline, and J.R. Cirrito. 2016. Redundant Gs-coupled serotonin receptors regulate amyloid-ß metabolism in vivo. Mol. Neurodegener. 11:45. https:// doi .org/ 10 .1186/ s13024 -016 -0112 -5
32. Fowler, S.W., A.C. Chiang, R.R. Savjani, M.E. Larson, M.A. Sherman, D.R. Schuler, J.R. Cirrito, S.E. Lesné, and J.L. Jankowsky. 2014. Genetic modulation of soluble Aß rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J. Neurosci. 34:7871-7885. https:// doi .org/ 10 .1523/ JNE URO SCI .0572 -14 .2014
33. Fox, J. 2003. Effect displays in R for generalised linear models. J. Stat. Softw. 8:1-27. https:// doi .org/ 10 .18637/ jss .v008 .i15
34. Fox, J., and M. Bouchet-Valat. 2017. Rcmdr: R Commander. http:// socserv .socsci .mcmaster .ca/ jfox/ Misc/ Rcmdr/ (accessed June 1, 2017).
35. Fox, J., and S. Weisberg. 2011. An R companion to applied regression. Second edition. Sage Publications, Thousand Oaks, CA. 472 pp.
36. Gandy, S., A.J. Simon, J.W. Steele, A.L. Lublin, J.J. Lah, L.C. Walker, A.I. Levey, G.A. Krafft, E. Levy, F. Checler, et al. 2010. Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid-beta oligomers. Ann. Neurol. 68:220-230.
37. Garza-Lombó, C., and M.E. Gonsebatt. 2016. Mammalian target of rapamycin: Its role in early neural development and in adult and aged brain function. Front. Cell. Neurosci. 10:157. https:// doi .org/ 10 .3389/ fncel .2016 .00157
38. Golde, T.E., P. Das, and Y. Levites. 2009. Quantitative and mechanistic studies of Abeta immunotherapy. CNS Neurol. Disord. Drug Targets. 8:31-49. https:// doi .org/ 10 .2174/ 187152709787601830
39. Golde, T.E., E.H. Koo, K.M. Felsenstein, B.A. Osborne, and L. Miele. 2013. γ-Secretase inhibitors and modulators. Biochim. Biophys. Acta. 1828:2898-2907. https:// doi .org/ 10 .1016/ j .bbamem .2013 .06 .005
40. Griffin, R.J., A. Moloney, M. Kelliher, J.A. Johnston, R. Ravid, P. Dockery, R. O'Connor, and C. O'Neill. 2005. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 93:105-117. https:// doi .org/ 10 .1111/ j .1471 -4159 .2004 .02949 .x
41. Günthard, H.F., M.S. Saag, C.A. Benson, C. del Rio, J.J. Eron, J.E. Gallant, J.F. Hoy, M.J. Mugavero, P.E. Sax, M.A. Thompson, et al. 2016. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society-USA Panel. JAMA. 316:191-210. https:// doi .org/ 10 .1001/ jama .2016 .8900
42. Hartman, R.E., Y. Izumi, K.R. Bales, S.M. Paul, D.F. Wozniak, and D.M. Holtzman. 2005. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci. 25:6213-6220. https:// doi .org/ 10 .1523/ JNE URO SCI .0664 -05 .2005
43. Hendrix, J.A., R.J. Bateman, H.R. Brashear, C. Duggan, M.C. Carrillo, L.J. Bain, R. DeMattos, R.G. Katz, S. Ostrowitzki, E. Siemers, et al. 2016. Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. Alzheimers Dement. 12:623-630. https:// doi .org/ 10 .1016/ j .jalz .2016 .02 .007
44. Herry, C., and J.P. Johansen. 2014. Encoding of fear learning and memory in distributed neuronal circuits. Nat. Neurosci. 17:1644-1654. https:// doi .org/ 10 .1038/ nn .3869
45. Hoeffer, C.A., and E. Klann. 2010. mTOR signaling: At the crossroads of plasticity, memory and disease. Trends Neurosci. 33:67-75. https:// doi .org/ 10 .1016/ j .tins .2009 .11 .003
46. Huang, W., P.J. Zhu, S. Zhang, H. Zhou, L. Stoica, M. Galiano, K. Krnjevic, G. Roman, and M. Costa-Mattioli. 2013. mTORC2 controls actin polymerization required for consolidation of long-term memory. Nat. Neurosci. 16:441-448. https:// doi .org/ 10 .1038/ nn .3351
47. Imbimbo, B.P., and G.A. Giardina. 2011. γ-Secretase inhibitors and modulators for the treatment of Alzheimer's disease: Disappointments and hopes. Curr. Top. Med. Chem. 11:1555-1570. https:// doi .org/ 10 .2174/ 156802611795860942
48. Jacobsen, H., L. Ozmen, A. Caruso, R. Narquizian, H. Hilpert, B. Jacobsen, D. Terwel, A. Tanghe, and B. Bohrmann. 2014. Combined treatment with a BACE inhibitor and anti-Aß antibody gantenerumab enhances amyloid reduction in APPLondon mice. J. Neurosci. 34:11621-11630. https:// doi .org/ 10 .1523/ JNE URO SCI .1405 -14 .2014
49. Jankowsky, J.L., H.H. Slunt, V. Gonzales, A.V. Savonenko, J.C. Wen, N.A. Jenkins, N.G. Copeland, L.H. Younkin, H.A. Lester, S.G. Younkin, and D.R. Borchelt. 2005. Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2:e355. https:// doi .org/ 10 .1371/ journal .pmed .0020355
50. Kerantzas, C.A., and W.R. Jacobs Jr. 2017. Origins of combination therapy for tuberculosis: Lessons for future antimicrobial development and application. MBio. 8:e01586-e16. https:// doi .org/ 10 .1128/ mBio .01586 -16
51. Knight, E.M., S.H. Kim, J.C. Kottwitz, A. Hatami, R. Albay, A. Suzuki, A. Lublin, C.M. Alberini, W.L. Klein, P. Szabo, et al. 2016. Effective anti-Alzheimer Aß therapy involves depletion of specific Aß oligomer subtypes. Neurol. Neuroimmunol. Neuroinflamm. 3:e237. https:// doi .org/ 10 .1212/ NXI .0000000000000237
52. Knowles, R.B., C. Wyart, S.V. Buldyrev, L. Cruz, B. Urbanc, M.E. Hasselmo, H.E. Stanley, and B.T. Hyman. 1999. Plaque-induced neurite abnormalities: Implications for disruption of neural networks in Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 96:5274-5279. https:// doi .org/ 10 .1073/ pnas .96 .9 .5274
53. Koffie, R.M., M. Meyer-Luehmann, T. Hashimoto, K.W. Adams, M.L. Mielke, M. Garcia-Alloza, K.D. Micheva, S.J. Smith, M.L. Kim, V.M. Lee, et al. 2009. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. USA. 106:4012-4017. https:// doi .org/ 10 .1073/ pnas .0811698106
54. Lacor, P.N., M.C. Buniel, P.W. Furlow, A.S. Clemente, P.T. Velasco, M. Wood, K.L. Viola, and W.L. Klein. 2007. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27:796-807. https:// doi .org/ 10 .1523/ JNE URO SCI .3501 -06 .2007
55. Lee, E.B., L.Z. Leng, B. Zhang, L. Kwong, J.Q. Trojanowski, T. Abel, and V.M. Lee. 2006. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem. 281:4292-4299. https:// doi .org/ 10 .1074/ jbc .M511018200
56. Levites, Y., P. Das, R.W. Price, M.J. Rochette, L.A. Kostura, E.M. McGowan, M.P. Murphy, and T.E. Golde. 2006a. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. 116:193-201. https:// doi .org/ 10 .1172/ JCI25410
57. Levites, Y., L.A. Smithson, R.W. Price, R.S. Dakin, B. Yuan, M.R. Sierks, J. Kim, E. McGowan, D.K. Reed, T.L. Rosenberry, et al. 2006b. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. FAS EB J. 20:2576-2578. https:// doi .org/ 10 .1096/ fj .06 -6463fje
58. Liu, P., M.N. Reed, L.A. Kotilinek, M.K. Grant, C.L. Forster, W. Qiang, S.L. Shapiro, J.H. Reichl, A.C. Chiang, J.L. Jankowsky, et al. 2015. Quaternary structure defines a large class of amyloid-ß oligomers neutralized by sequestration. Cell Reports. 11:1760-1771. https:// doi .org/ 10 .1016/ j .celrep .2015 .05 .021
59. Maren, S., K.L. Phan, and I. Liberzon. 2013. The contextual brain: Implications for fear conditioning, extinction and psychopathology. Nat. Rev. Neurosci. 14:417-428. https:// doi .org/ 10 .1038/ nrn3492
60. May, P.C., R.A. Dean, S.L. Lowe, F. Martenyi, S.M. Sheehan, L.N. Boggs, S.A. Monk, B.M. Mathes, D.J. Mergott, B.M. Watson, et al. 2011. Robust central reduction of amyloid-ß in humans with an orally available, non-peptidic ß-secretase inhibitor. J. Neurosci. 31:16507-16516. https:// doi .org/ 10 .1523/ JNE URO SCI .3647 -11 .2011
61. Mayford, M., M.E. Bach, Y.Y. Huang, L. Wang, R.D. Hawkins, and E.R. Kandel. 1996. Control of memory formation through regulated expression of a CaMKII transgene. Science. 274:1678-1683. https:// doi .org/ 10 .1126/ science .274 .5293 .1678
62. Nixon, R.A. 2007. Autophagy, amyloidogenesis and Alzheimer disease. J. Cell Sci. 120:4081-4091. https:// doi .org/ 10 .1242/ jcs .019265
63. Nixon, R.A., and D.S. Yang. 2011. Autophagy failure in Alzheimer's disease- Locating the primary defect. Neurobiol. Dis. 43:38-45. https:// doi .org/ 10 .1016/ j .nbd .2011 .01 .021
64. Oddo, S. 2012. The role of mTOR signaling in Alzheimer disease. Front. Biosci. (Schol. Ed.). 4:941-952. https:// doi .org/ 10 .2741/ s310
65. Perry, D., R. Sperling, R. Katz, D. Berry, D. Dilts, D. Hanna, S. Salloway, J.Q. Trojanowski, C. Bountra, M. Krams, et al. 2015. Building a roadmap for developing combination therapies for Alzheimer's disease. Expert Rev. Neurother. 15:327-333. https:// doi .org/ 10 .1586/ 14737175 .2015 .996551
66. Rasool, S., H. Martinez-Coria, J.W. Wu, F. LaFerla, and C.G. Glabe. 2013. Systemic vaccination with anti-oligomeric monoclonal antibodies improves cognitive function by reducing Aß deposition and tau pathology in 3xTg-AD mice. J. Neurochem. 126:473-482. https:// doi .org/ 10 .1111/ jnc .12305
67. R Core Team. 2017. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:// www .r -project .org/ (accessed June 1, 2017).
68. Rodgers, S.P., H.A. Born, P. Das, and J.L. Jankowsky. 2012. Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol. Neurodegener. 7:28. https:// doi .org/ 10 .1186/ 1750 -1326 -7 -28
69. Roscic, A., B. Baldo, C. Crochemore, D. Marcellin, and P. Paganetti. 2011. Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. J. Neurochem. 119:398-407. https:// doi .org/ 10 .1111/ j .1471 -4159 .2011 .07435 .x
70. Sardiello, M., M. Palmieri, A. di Ronza, D.L. Medina, M. Valenza, V.A. Gennarino, C. Di Malta, F. Donaudy, V. Embrione, R.S. Polishchuk, et al. 2009. A gene network regulating lysosomal biogenesis and function. Science. 325:473-477.
71. Saxton, R.A., and D.M. Sabatini. 2017. mTOR signaling in growth, metabolism, and disease. Cell. 168:960-976. https:// doi .org/ 10 .1016/ j .cell .2017 .02 .004
72. Settembre, C., C. Di Malta, V.A. Polito, M. Garcia Arencibia, F. Vetrini, S. Erdin, S.U. Erdin, T. Huynh, D. Medina, P. Colella, et al. 2011. TFEB links autophagy to lysosomal biogenesis. Science. 332:1429-1433. https:// doi .org/ 10 .1126/ science .1204592
73. Shankar, G.M., B.L. Bloodgood, M. Townsend, D.M. Walsh, D.J. Selkoe, and B.L. Sabatini. 2007. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27:2866- 2875. https:// doi .org/ 10 .1523/ JNE URO SCI .4970 -06 .2007
74. Shankar, G.M., S. Li, T.H. Mehta, A. Garcia-Munoz, N.E. Shepardson, I. Smith, F.M. Brett, M.A. Farrell, M.J. Rowan, C.A. Lemere, et al. 2008. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14:837-842. https:// doi .org/ 10 .1038/ nm1782
75. Sharoar, M.G., Q. Shi, Y. Ge, W. He, X. Hu, G. Perry, X. Zhu, and R. Yan. 2016. Dysfunctional tubular endoplasmic reticulum constitutes a pathological feature of Alzheimer's disease. Mol. Psychiatry. 21:1263-1271. https:// doi .org/ 10 .1038/ mp .2015 .181
76. Siemers, E., M. Skinner, R.A. Dean, C. Gonzales, J. Satterwhite, M. Farlow, D. Ness, and P.C. May. 2005. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol. 28:126-132. https:// doi .org/ 10 .1097/ 01 .wnf .0000167360 .27670 .29
77. Stephenson, D., D. Perry, C. Bens, L.J. Bain, D. Berry, M. Krams, R. Sperling, D. Dilts, J. Luthman, D. Hanna, et al. 2015. Charting a path toward combination therapy for Alzheimer's disease. Expert Rev. Neurother. 15:107-113. https:// doi .org/ 10 .1586/ 14737175 .2015 .995168
78. Stern, E.A., B.J. Bacskai, G.A. Hickey, F.J. Attenello, J.A. Lombardo, and B.T. Hyman. 2004. Cortical synaptic integration in vivo is disrupted by amyloid- beta plaques. J. Neurosci. 24:4535-4540. https:// doi .org/ 10 .1523/ JNE URO SCI .0462 -04 .2004
79. Stokin, G.B., C. Lillo, T.L. Falzone, R.G. Brusch, E. Rockenstein, S.L. Mount, R. Raman, P. Davies, E. Masliah, D.S. Williams, and L.S. Goldstein. 2005. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science. 307:1282-1288. https:// doi .org/ 10 .1126/ science .1105681
80. Talboom, J.S., R. Velazquez, and S. Oddo. 2015. The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer's disease. NPJ Aging Mech. Dis. 1:15008. https:// doi .org/ 10 .1038/ npjamd .2015 .8
81. Tsai, J., J. Grutzendler, K. Duff, and W.B. Gan. 2004. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat. Neurosci. 7:1181-1183. https:// doi .org/ 10 .1038/ nn1335
82. Ulrich, J.D., J.M. Burchett, J.L. Restivo, D.R. Schuler, P.B. Verghese, T.E. Mahan, G.E. Landreth, J.M. Castellano, H. Jiang, J.R. Cirrito, and D.M. Holtzman. 2013. In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis. Mol. Neurodegener. 8:13. https:// doi .org/ 10 .1186/ 1750 -1326 -8 -13
83. Venables, W.N., and B.D. Ripley. 2002. Modern Applied Statistics with S. Fourth edition. Spring er-Verlag, New York. 497 pp.
84. Walsh, D.M., I. Klyubin, J.V. Fadeeva, W.K. Cullen, R. Anwyl, M.S. Wolfe, M.J. Rowan, and D.J. Selkoe. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:535-539. https:// doi .org/ 10 .1038/ 416535a
85. Wang, A., P. Das, R.C. Switzer III, T.E. Golde, and J.L. Jankowsky. 2011. Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J. Neurosci. 31:4124-4136. https:// doi .org/ 10 .1523/ JNE URO SCI .5077 -10 .2011
86. Wong, G.T., D. Manfra, F.M. Poulet, Q. Zhang, H. Josien, T. Bara, L. Engstrom, M. Pinzon-Ortiz, J.S. Fine, H.J. Lee, et al. 2004. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279:12876-12882. https:// doi .org/ 10 .1074/ jbc .M311652200
87. Youmans, K.L., S. Leung, J. Zhang, E. Maus, K. Baysac, G. Bu, R. Vassar, C. Yu, and M.J. LaDu. 2011. Amyloid-ß42 alters apolipoprotein E solubility in brains of mice with five familial AD mutations. J. Neurosci. Methods. 196:51-59. https:// doi .org/ 10 .1016/ j .jneumeth .2010 .12 .025
88. Zeileis, A. 2004. Econometric computing with HC and HAC covariance matrix estimators. J. Stat. Softw. 11:1-17. https:// doi .org/ 10 .18637/ jss .v011 .i10
89. Zhang, Y.D., and J.J. Zhao. 2015. TFEB participates in the Abeta-induced pathogenesis of Alzheimer's disease by regulating the autophagy-lysosome pathway. DNA Cell Biol. 34:661-668. https:// doi .org/ 10 .1089/ dna .2014 .2738
90. Zhang, W., J. Hao, R. Liu, Z. Zhang, G. Lei, C. Su, J. Miao, and Z. Li. 2011. Soluble Aß levels correlate with cognitive deficits in the 12-month-old APPswe/ PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 222:342- 350. https:// doi .org/ 10 .1016/ j .bbr .2011 .03 .072